Smith & Nephew (LON:SN) Rating Lowered to Sector perform at Royal Bank Of Canada

Smith & Nephew (LON:SN) was downgraded by analysts at Royal Bank Of Canada to a “sector perform” rating in a report released on Wednesday, MarketBeat reports. They currently have a GBX 1,350 target price on the stock, down from their prior target price of GBX 1,700. Royal Bank Of Canada’s price objective would indicate a potential upside of 10.38% from the company’s current price.

A number of other equities research analysts have also recently commented on SN. Panmure Gordon reaffirmed a “hold” rating and issued a GBX 1,200 target price on shares of Smith & Nephew in a report on Tuesday, December 9th. Citigroup upped their price objective on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Price Performance

Shares of Smith & Nephew stock opened at GBX 1,223 on Wednesday. The stock has a market cap of £13.41 billion, a PE ratio of 44.03, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The firm’s 50 day moving average price is GBX 1,293.57 and its 200-day moving average price is GBX 1,259.25.

Insider Activity at Smith & Nephew

In related news, insider Deepak Nath sold 1,240 shares of Smith & Nephew stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total value of £15,586.80. 0.19% of the stock is owned by insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.